Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Effects of cilostazol on platelet function.

S Uehara1, A Hirayama

  • 1Department of Internal Medicine, Tonan Hospital, Sapporo, Japan.

Arzneimittel-Forschung
|December 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dipole Strength Distribution of ^{8}He and Decay Characteristics.

Physical review letters·2026
Same author

Magicity versus Superfluidity around ^{28}O viewed from the Study of ^{30}F.

Physical review letters·2024
Same author

Publisher Correction: First observation of <sup>28</sup>O.

Nature·2023
Same author

First observation of <sup>28</sup>O.

Nature·2023
Same author

Observation of a correlated free four-neutron system.

Nature·2022
Same author

Extending the Southern Shore of the Island of Inversion to ^{28}F.

Physical review letters·2020

Cilostazol effectively inhibits platelet aggregation, showing a stronger effect than trapidil in vitro. Oral administration in patients with cerebral vascular diseases significantly reduced platelet aggregation.

Area of Science:

  • Pharmacology
  • Cardiovascular Research
  • Hematology

Background:

  • Platelet aggregation plays a critical role in thrombotic events.
  • Cilostazol is a medication with known vasodilatory and antiplatelet properties.
  • Understanding the comparative efficacy of antiplatelet agents is crucial for clinical practice.

Purpose of the Study:

  • To evaluate the antiplatelet efficacy of cilostazol (OPC-13013).
  • To compare the in vitro antiplatelet activity of cilostazol with trapidil.
  • To assess the in vivo antiplatelet effect of oral cilostazol in patients with stable cerebral vascular diseases.

Main Methods:

  • In vitro assays were performed to measure platelet aggregation inhibition.
  • Trapedil was used as a control in in vitro experiments.

Related Experiment Videos

  • In vivo study involved oral administration of cilostazol (100 mg/d for 4 weeks) to patients with stable cerebral vascular diseases.

    • Main Results:

    • Cilostazol demonstrated an in vitro platelet aggregation inhibitory effect approximately 10 times greater than trapidil.
    • Oral administration of cilostazol in patients resulted in a statistically significant reduction in platelet aggregation.

    Conclusions:

    • Cilostazol exhibits potent antiplatelet activity, superior to trapidil in vitro.
    • Cilostazol is effective in reducing platelet aggregation in patients with cerebral vascular diseases.
    • These findings support the therapeutic potential of cilostazol in managing conditions associated with platelet hyperactivity.